Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Neovasc Inc (NVCN.TO)

Neovasc Inc (NVCN.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,607
  • Shares Outstanding, K 11,133
  • Annual Sales, $ 1,749 K
  • Annual Income, $ -108,043 K
  • 60-Month Beta 3.61
  • Price/Sales 4.01
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.06
  • Earnings Per Share ttm 25.88
  • Most Recent Earnings -0.83 on 09/30/19
  • Next Earnings Date 03/30/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Medical Devices

    TSX Bottom 100 Stocks

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.50
  • Number of Estimates 1
  • High Estimate -1.50
  • Low Estimate -1.50
  • Prior Year -2.00
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.08 +10.58%
on 03/24/20
3.82 -39.79%
on 03/03/20
-1.29 (-35.93%)
since 02/27/20
3-Month
2.08 +10.58%
on 03/24/20
11.20 -79.46%
on 12/31/19
-2.51 (-52.18%)
since 12/27/19
52-Week
2.08 +10.58%
on 03/24/20
11.40 -79.82%
on 05/23/19
-2.90 (-55.77%)
since 03/27/19

Most Recent Stories

More News
Transcatheter Devices Market Size, Share, Applications | Global Report 2026

In accordance with the study held by Acumen Research, the Transcatheter Devices Market size is projected to reach US$ 19.4 Bn by 2026 with a CAGR of 12% throughout the forecast period 2019 to 2026. The...

BSX : 30.61 (-2.58%)
EW : 198.15 (-0.65%)
NVCN.TO : 2.30 (-9.09%)
Neovasc to Report Fourth Quarter and Full Year 2019 Financial Results on March 30, 2020

Vancouver, British Columbia--(Newsfile Corp. - March 17, 2020) - (NASDAQ: (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally...

NVCN : 1.6600 (-9.78%)
NVCN.TO : 2.30 (-9.09%)
Neovasc to Report Fourth Quarter and Full Year 2019 Financial Results on March 30, 2020

via NEWMEDIAWIRE -- Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment...

NVCN : 1.6600 (-9.78%)
NVCN.TO : 2.30 (-9.09%)
Global Transcatheter Mitral Valve Repair and Replacement Market Set for Rapid Growth During 2020 - 2025 | Edwards Lifesciences, Medtronic Plc, Abbott Laboratories, Neovasc Inc, etc

MENAFN11032020007010647ID1099830997

ABT : 74.56 (-1.65%)
EW : 198.15 (-0.65%)
MDT : 89.89 (-2.23%)
NVCN.TO : 2.30 (-9.09%)
Global Valvular Heart Disease Treatment Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025

, a new addition to the catalog of Fior Markets, provides an overview of the current state of the market and its evolution. The report contains a forecast of 2019 and ending 2025 with key aspects such...

BSX : 30.61 (-2.58%)
CRY : 15.52 (-4.55%)
EW : 198.15 (-0.65%)
LIVN : 43.57 (+2.21%)
MDT : 89.89 (-2.23%)
NVCN.TO : 2.30 (-9.09%)
Neovasc Updates Investors at SVB Leerink 9th Annual Global Healthcare Conference

Vancouver, British Columbia--(Newsfile Corp. - March 4, 2020) - (NASDAQ: NVCN)  (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve...

NVCN : 1.6600 (-9.78%)
NVCN.TO : 2.30 (-9.09%)
Neovasc Updates Investors at SVB Leerink 9th Annual Global Healthcare Conference

via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive...

NVCN : 1.6600 (-9.78%)
NVCN.TO : 2.30 (-9.09%)
Neovasc Reducer Featured in Peer Reviewed EuroIntervention and PCR Online

Vancouver, British Columbia--(Newsfile Corp. - March 3, 2020) - (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement...

NVCN : 1.6600 (-9.78%)
NVCN.TO : 2.30 (-9.09%)
Neovasc Reducer Featured in Peer Reviewed EuroIntervention and PCR Online

via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive...

NVCN : 1.6600 (-9.78%)
NVCN.TO : 2.30 (-9.09%)
Pediatric Asthma Monitor Market Fundamental Analysis By Top Key Players GE Global Research Company, Capnia Inc, Allgene LLC

Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Pediatric Asthma Monitor market in the latest research report...

MDSY : 0.73 (+4.29%)
NVCN.TO : 2.30 (-9.09%)
UCMDF : 0.1000 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 2.60
1st Resistance Point 2.45
Last Price 2.30
1st Support Level 2.18
2nd Support Level 2.06

See More

52-Week High 11.40
Fibonacci 61.8% 7.84
Fibonacci 50% 6.74
Fibonacci 38.2% 5.64
Last Price 2.30
52-Week Low 2.08

See More

Business Summary

Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar